Over the past 12‑18 months, the Amphotericin B Liposome for Injection market has witnessed a cascade of strategic moves that are reshaping the competitive landscape. In March 2023, Gilead Sciences entered a global distribution partnership with Mylan to broaden access in emerging economies, while in August 2023 Pfizer completed the acquisition of niche biotech CureBio, adding a late‑stage liposomal formulation pipeline to its portfolio. The same year, Bristol‑Myers Squibb launched a next‑generation, low‑infusion‑time liposomal amphotericin B product (AmphoLipo™) that leverages a proprietary phospholipid‑stabilized carrier, receiving fast‑track designation from the FDA in February 2024. Regulatory momentum accelerated when the European Medicines Agency revised its guidance on nanomedicine safety, shortening review cycles for liposomal antifungals. Meanwhile, venture capital activity surged, with a $85 million Series B round led by OrbiMed backing the Israeli startup LipoPharm, earmarked for a new manufacturing site in Singapore. These developments collectively signal a shift toward faster‑acting, globally‑scaled solutions and underscore the dynamic Amphotericin B Liposome for Injection industry trends shaping the next growth phase.
